A Multicenter, Prospective, Noninterventional Study in a Norwegian Cohort of Patients with Moderate-to-Severe Allergic Rhinitis Treated with MP-AzeFlu
Autor: | Ralph Dollner, Sinan Dheyauldeen, Petter Lorentz Larsen, Sverre Steinsvåg |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Moderate to severe
lcsh:Immunologic diseases. Allergy medicine.medical_specialty Visual analogue scale effectiveness seasonal allergic rhinitis Norwegian Fluticasone propionate perennial allergic rhinitis 03 medical and health sciences 0302 clinical medicine MP-AzeFlu Internal medicine medicine Immunology and Allergy real-life 030223 otorhinolaryngology Morning Asthma Vas score Azelastine business.industry fluticasone propionate Norway visual analog scale Articles medicine.disease lcsh:Otorhinolaryngology lcsh:RF1-547 language.human_language 030228 respiratory system Otorhinolaryngology Cohort language business lcsh:RC581-607 control medicine.drug |
Zdroj: | Allergy & Rhinology, Vol 8 (2017) Allergy & Rhinology |
ISSN: | 2152-6567 |
Popis: | Background Allergic Rhinitis and its Impact on Asthma guidelines recently recommended a treatment strategy for allergic rhinitis (AR) based on disease control rather than symptom severity by using a visual analog scale (VAS) to categorize control Objectives To evaluate the effectiveness of MP-AzeFlu (Dymista®) by using this VAS in routine clinical practice in Norway. MP-AzeFlu comprises a novel formulation that contains azelastine hydrochloride, fluticasone propionate and excipients delivered in a single spray. Methods This multicenter, prospective, noninterventional study enrolled patients (n = 160) with moderate-to-severe AR and acute symptoms who were eligible to receive treatment with MP-AzeFlu according to its summary of product characteristics. Patients assessed symptom severity by using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) in the morning before MP-AzeFlu use on days 0, 1, 3, 7, and after ~14 days. On day 3, the patients assessed their level of disease control as well controlled, partly controlled, or uncontrolled. The proportion of Norwegian patients who achieved defined VAS score cutoffs for “well-controlled” and “partly controlled” AR were also calculated. Results MP-AzeFlu reduced the mean ± standard deviation VAS score from 68.1 ± 16.4 mm at baseline to 37.4 ± 25.9 mm on the last day, a reduction of 30.8 ± 27.2 mm. The results were consistent, irrespective of disease severity, phenotype (i.e., seasonal AR [SAR], perennial AR [PAR], SAR plus PAR, unknown) or age (i.e., 12–17, 18–65, and >65 years). Of the patients (with recorded data), 88.1% considered their symptoms to be partly or well controlled at day 3; and 19.5, 32.0, 50.0, and 61.0% of the patients achieved a ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7, and the last day, respectively. Conclusions MP-AzeFlu provided rapid sustained symptom control in a routine clinical practice in Norway, which provided support for its effectiveness for the treatment of AR in real life. |
Databáze: | OpenAIRE |
Externí odkaz: |